

Antibody-Mediated Rejection Market is Estimated to Witness Growth Owing to Novel Biologics

The Antibody-mediated Rejection (AMR) Market encompasses a range of diagnostic assays, therapeutic antibodies, and immunomodulatory agents designed to identify and manage antibody-mediated organ rejection in transplant recipients. These products deliver rapid, sensitive detection of donor-specific antibodies, enabling clinicians to initiate timely interventions and reduce graft loss. Advanced assays such as complement-dependent cytotoxicity testing, flow cytometry crossmatch, and Luminex-based single-antigen bead tests offer high specificity and reproducibility, while novel biologics—including monoclonal antibodies targeting complement factors and B-cell pathways—provide improved efficacy with fewer off-target effects. [Antibody-mediated Rejection Market](#) growing adoption of personalized immunosuppressive regimens, driven by comprehensive market insights and rigorous market research, has elevated the need for precise monitoring tools that mitigate long-term graft dysfunction. Furthermore, streamlined workflows and automated platforms enhance laboratory throughput, addressing rising demand across high-volume transplant centers. As healthcare providers emphasize value-based care, cost-effective solutions that reduce hospitalization and re-transplantation rates are gaining traction. Continuous innovation in assay sensitivity and therapeutic delivery is expected to sustain robust market growth.

The antibody-mediated rejection market is estimated to be valued at USD 142.7 Mn in 2025 and is expected to reach USD 331.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2032.

Key Takeaways

Key players operating in the Antibody-mediated Rejection Market are

- CSL Behring,
- Hansa Biopharma
- AB,
- Viela Bio,
- Janssen Biotech
- Pfizer.

These market companies have established a strong presence through strategic partnerships and robust product pipelines. CSL Behring leverages its immunology expertise to advance complement-targeted therapies, while Hansa Biopharma AB focuses on imlifidase, an enzyme that rapidly cleaves immunoglobulin G to prevent acute rejection. Viela Bio's proprietary platforms support novel antibody development, and Janssen Biotech collaborates with transplant centers to optimize dosing regimens. Pfizer's broad biopharmaceutical portfolio and global manufacturing reach further amplify its ability to address diverse patient needs. Collectively, these market players drive the competitive landscape, continuously investing in R&D to expand indications and improve patient outcomes.

The global AMR Market presents significant market opportunities in underserved regions, where transplant rates are rising but diagnostic and therapeutic access remains limited. As emerging economies enhance healthcare infrastructure and reimbursement frameworks, there is scope to introduce point-of-care testing and mobile laboratory units to reduce turnaround times. Collaborations between market research institutes, academic centers, and biotech firms can foster innovation in low-cost assay development.

Additionally, combination therapies that integrate plasmapheresis, intravenous immunoglobulin, and targeted biologics represent a key opportunity for comprehensive rejection management protocols. The growing emphasis on real-world evidence and patient-reported outcomes also opens avenues for digital health solutions, remote monitoring platforms, and data analytics services that support personalized treatment strategies. Such market opportunities are anticipated to attract new entrants and catalyze

